Toxoplasmosis
14
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
14%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis
Isolated Positive Toxoplasma Gondii PCR in Blood
Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)
Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)
Latent Toxoplasmosis in Females With Borderline Personality Disorder
Toxoplasma Gondii Infection in Both Children and Adult Patients With Hematological Malignancies
Measuring the Prevalence of Toxoplasmosis and Its Socio-economic Consequences
Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Antiretroviral Drug Interaction Study in Volunteers With HIV
Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis